Effects of heparan-like polymers associated with growth factors on osteoblast proliferation and phenotype expression

Journal of Biomedical Materials Research

Volumn 44, Issue 1, 1999, Pages 63-72

  Blanquaert, F ^a   Barritault, D ^a   Caruelle, J P ^a  

^a Université Paris Est Créteil   (France)

Author keywords

DNA synthesis; Heparan like molecules; Heparin binding growth factors; Osteoblast; Phenotype expression

Indexed keywords

ALKALINE PHOSPHATASE; BMP2 PROTEIN, MOUSE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; CYCLIC AMP; DEXTRAN; DNA; FIBROBLAST GROWTH FACTOR 2; GROWTH PROMOTOR; HEPARIN; PARATHYROID HORMONE; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; HEPARAN; POLYMER;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL DIVISION; CELL STRAIN 3T3; CYTOLOGY; DRUG EFFECT; KINETICS; METABOLISM; MOUSE; OSTEOBLAST; PHYSIOLOGY; ANIMAL CELL; BONE REMODELING; CELL PROLIFERATION; DNA SYNTHESIS; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; RECEPTOR AFFINITY;

3T3 CELLS; ALKALINE PHOSPHATASE; ANIMALS; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CYCLIC AMP; DEXTRANS; DNA; FIBROBLAST GROWTH FACTOR 2; GROWTH SUBSTANCES; HEPARIN; KINETICS; MICE; OSTEOBLASTS; PARATHYROID HORMONE; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

AGENTS; ANIMAL CELL CULTURE; BIOSYNTHESIS; CATALYST ACTIVITY; DNA; ENZYMES; GENETIC ENGINEERING; HORMONES; POLYSACCHARIDES;

PHENOTYPE EXPRESSION; REGENERATING AGENTS (RGTA);

BIOMATERIALS;

EID: 0032600241     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-4636(199901)44:1<63::aid-jbm7>3.0.co;2-s     Document Type: Article

References (50)

1. Albo D, Long C, Jhala N, Granick MS, Wang T, Meddahi A, Barritault D, Solomon MP. Modulation of cranial bone healing with a heparin-like dextran derivative. J Craniofac Surg 1996; 7:19-22.
2. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP. Heparan-like molecules induce the repair of skull defects. Bone 1995;17:499-506.
3. Gautron J, Kedzia C, Husmann I, Barritault D. Acceleration of the regeneration of skeletal muscles in adult rats by dextran derivatives. C R Acad Sci III Vie 1995;318:671-676.
4. Lafont J, Baroukh B, Meddahi A, Caruelle JP, Barritault D, Saffar JL. Derivatized dextrans (CMDBS) as promoters of bone healing. Factors influencing their effectiveness. Cell Mater 1994;4:219-230.
5. Meddahi A, Blanquaert F, Saffar JL, Colombier ML, Caruelle JP, Jozefonvicz J, Barritault D. New approaches to tissue regeneration and repair. Path Res Pract 1994;190:923-928.
6. Meddahi A, Benoit J, Ayoub N, Sézeur A, Barritault D. Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage. J Biomed Mater Res 1996;31:293-297.
7. Tardieu M, Gamby C, Avramoglou T, Josefonvicz J, Barritault D. Derivatized dextrans mimic heparin as stabilizers, potentiators and protectors of acidic or basic FGFs. J Cell Physiol 1992; 150:194-203.
8. Tardieu M, Slaoui F, Josefonvicz J, Courty J, Gamby C, Barritault D. Biological and binding studies of acidic fibroblast growth factor in the presence of substituted dextran. J Biomater Sci Polymer Ed 1989;1:63-70.
9. McCaffrey Y, Falcone D, Du B. Transforming growth factor-β1 is a heparin-binding protein: Identification of putative heparin-binding regions and isolation of heparin with varying affinity for TGF-β1. J Cell Physiol 1992;152:430-440.
10. McCaffrey Y, Falcone D, Brayton CF, Agarwal LA, Welt FGP, Weksler BB. Transforming growth factor-b is potentiated by heparin via dissociation of the transforming growth factor-b/ a2-macroglobulin inactive complex. J Cell Biol 1989;109:441-448.
11. McCaffrey Y, Falcone D, Vicente D, Du DB, Consigli S, Borth W. Protection of transforming growth factor-β1 activity by heparin and fucoidan. J Cell Physiol 1994;159:51-59.
12. Ruoslahti E, Yamaguchi D. Proteoglycans as modulators of growth factor activities. Cell 1991;64:867-869.
13. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988;107:743-751
14. Sommer A, Rifkin DB. Interaction of heparin with human basic fibroblast growth factor: Protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol 1989;138:215-220.
15. Flaumenhaft R, Moscatelli D, Saksela O, Rifkin DB. Role of extracellular matrix in the action of basic fibroblast growth factor: Matrix as a source of gorwth factor for long-term stimulation of plasminogen activator production and DNA synthesis. J Cell Physiol 1989;140:75-81.
16. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. J Biol Chem 1986;261: 12665-12674.
17. Presta M, Maier JA, Rusnati M, Ragnotti G. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J Cell Physiol 1989;140:68-74.
18. Lopez-Casillas F, Payne HM, Andres JL, Massagué J. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: Mapping of ligand binding and GAG attachment sites. J Cell Biol 1994;124:557-568.
19. Lopez-Casillas F, Wrana JL, Massagué J. Betaglycan presents ligand to the TGF-β signaling receptor. Cell 1993;73:1435-1444.
20. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994;79:1015-1024.
21. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991;64:841-848.
22. Meddahi A, Lemdjabar H, Caruelle J-P, Barritault D, Hornebeck W. Inhibition by dextran derivatives of FGF-2 plasmin-mediated degradation. Biochimie 1995;77:703-706.
23. Meddahi A, Lemdjabar H, Caruelle J-P, Barritault D, Hornebeck W. Inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int J Biol Macromol 1996;18:141-145.
24. Walsh R, Dillon T, Scicchitano R, McLennan G. Heparin and heparan sulfate are inhibitors of human leucocyte elastase. Clin Sci 1991;81:341-346.
25. Baylink DJ, Finkelman RD, Mohan SE. Growth factors to stimulate bone formation. J Bone Miner Res. 1993;8(2):S565-S572.
26. Bourque WT, Gross M, Hall BK. Expression of four growth factors during fracture repair. Int J Dev Biol 1993;37:573-579.
27. Canalis E. Skeletal growth factors. In Feldman D, Marcus R, Kelsey Jr J, editors: Osteoporosis. San Diego, Academic Press; 1996. p 261-279.
28. Joyce ME, Jingushi S, Scully SP, Bolander ME. Role of growth factors in fracture healing. Preg Clin Biol Res 1991;365:391-416.
29. Sampath TK, Muthukumaran N, Reddi AH. Isolation of osteogenin, an extracellular matrix-associated, bone-inductive protein, by heparin affinity chromatography. Proc Natl Acad Sci USA 1987;84:7109-7113.
30. Andrew JG, Hoyland J, Andrew SM, Freemont AJ, Marsh D. Demonstration of TGF-beta 1 mRNA by in situ hybridization in normal human fracture healing. Calcif Tissue Int 1993;52: 74-78.
31. Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Griffin GL, Senior RM, Deuel TF. Platelet-derived growth factor and transforming growth factor-β enhance tissue repair activities by unique mechanisms. J Cell Biol 1989;109:429-440.
32. Beck SL, Deguzman L, Lee WP, Xu Y, McFatridge A, Gillett NA, Amento EP. IGF-β1 induces bone closure of skull defects. J Bone Miner Res 1991;11:1257-1265.
33. Marden L, Hollinger JO, Chaudhari A. Recombinant human bone morphogenetic protein-2 is superior to demineralized bone matrix in repairing craniotomy defects in rats. J Biomed Mater Res 1994;28:1127-1138.
34. Jingushi S, Heydemann A, Kana SK, Macey LR, Bolander ME. Acidic fibroblast growth factor (aFGF) injection stimulates cartilage enlargement and inhibits cartilage gene expression in rat fracture healing. J Orthop Res 1990;8:364-371.
35. Lind M, Schumacker B, Soballe K, Keller J, Melsen F, Bunger C. Transforming growth factor-β enhances fracture healing in rabbit tibiae. Acta Orthop Scand 1993;64:553-556.
36. Kawaguchi H, Kurokawa T, Hanada K, Hiyama Y, Tamura M, Ogata E, Matsumoto T. Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats. Endocrinology 1994;135:774-781.
37. Cook SD, Baffes GC, Wolfe MW, Sampath TK, Rueger DC. Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model. Clin Orthop Rel Res 1994;301:302-312.
38. Yasko AW, Lane JM, Fellinger EJ. The healing of segmental bone defects induced by recombinant human bone morphogenetic protein (rhBMP-2). J Bone Joint Surg 1992;74-A:659-670.
39. Marden LJ, Fan RSP, Pierce GF, Reddi AH, Hollinger JO. Platelet-derived growth factor inhibits bone regeneration induced by osteogenin, a bone morphogenetic protein, in rat craniotomy defects. J Clin Invest 1993;92:2897-2905.
40. Mauzac M, Maillet F, Jozefonvicz J, Kazatchkine M. Anti-complementary activity of dextran derivatives. Biomaterials 1985;6:61-63.
41. Abraham J, Merjia A, Whang J. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986;233:545-548.
42. Sudo H, Kodama H, Amagai Y, Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line from newborn mouse calvaria. J Cell Biol 1983;96:191-198.
43. Quarles LD, Yohay DA, Lever LW, Canton R, Wenstrup RJ. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: An in vitro model of osteoblast development. J Bone Miner Res 1992;7:683-692.
44. Hurley MM, Gronowicz G, Kream BE, Raisz LG. Effect of heparin on bone formation in cultured fetal rat calvaria. Calcif Tissue Int 1990;46:183-188.
45. Bagheri-Yarmand R, Morere JF, Letourneur D, Jozefonvicz J, Israel L, Crepin M. Inhibitory effects of dextran derivatives in vitro on the growth characteristics of premalignant and malignant human mammary epithelial cell lines. Anticancer Res. 1992;12:1641-1646.
46. Letourneur D, Logeart D, Avramoglou T, Jozefonvicz J. Anti-proliferative capacity of synthetic dextrans on smooth muscle cell growth: The model of derivatized dextrans as heparin-like polymers. J Biomater Sci, Polym Edn 1993;4:431-444.
47. Berrada S, Amedee J, Avramoglou T, Jozefonvicz J, Harmand MF. Effect of a derivatized dextran on human osteoblast growth and phenotype expression. J Biomater Sci Polym Edn 1994;6:211-222.
48. Moscatelli D. High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol 1987;131:123-130.
49. Hurley MM, Kream BE, Raisz LG. Structural determinants of the capacity of heparin to inhibit collagen synthesis in 21-day fetal rat calvariae. J Bone Miner Res 1990;5:1127-1133.
50. Gao G, Goldfarb M. Heparin can activate a receptor tyrosine kinase. EMBO J 1995;14:2183-2190